Breaking News, Collaborations & Alliances

Rhythm, Takeda Enter Development Agreement

To develop and commercialize T-3525770 (now RM-853) for the treatment of Prader-Willi Syndrome

Rhythm Pharmaceuticals has acquired exclusive, worldwide rights from Takeda to develop and commercialize T-3525770 (now RM-853).    RM-853 is a potent, orally available ghrelin o-acyltransferase (GOAT) inhibitor currently in preclinical development for Prader-Willi Syndrome (PWS). PWS is a rare genetic disorder that results in hyperphagia and early-onset, life-threatening obesity, for which there are no approved therapeutic options.   Ghrelin is an orexigenic peptide, secreted by...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters